Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms

• Published in: European urology 2023-08, Vol.84 (2), p.207-222
• Main Authors: Gravas, Stavros, Gacci, Mauro, Gratzke, Christian, Herrmann, Thomas R.W., Karavitakis, Markos, Kyriazis, Iason, Malde, Sachin, Mamoulakis, Charalampos, Rieken, Malte, Sakalis, Vasileios I., Schouten, Natasha, Speakman, Mark J., Tikkinen, Kari A.O., Cornu, Jean-Nicolas
• Format: Article
• Language: English
• Subjects: Conservative management; Diagnostics; European Association of Urology guidelines; Humans; Life Sciences; Lower Urinary Tract Symptoms - diagnosis; Lower Urinary Tract Symptoms - etiology; Lower Urinary Tract Symptoms - therapy; Male; Male lower urinary tract symptoms; Nocturia; Patient; Pharmacological management; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - diagnosis; Prostatic Hyperplasia - therapy; Prostatic Neoplasms - complications; Surgical management; Treatment; Urinalysis - adverse effects; Urinary incontinence; Urology
• ISSN: 0302-2838; 1873-7560; 1421-993X
• DOI: 10.1016/j.eururo.2023.04.008

Male lower urinary tract dysfunction represents a common problem in the community. Physicians should approach these patients based on the best available evidence. This summary provides the up-to-date recommendations for the evaluation and the management of men with lower urinary tract symptoms. Lower urinary tract symptoms (LUTS) are common, often bothersome, and have multifactorial aetiology. To present a summary of the 2023 version of the European Association of Urology guidelines on the management of male LUTS. A structured literature search from 1966 to 2021 selected the articles with the highest certainty evidence. The Delphi technique consensus approach was used to develop the recommendations. The assessment of men with LUTS should be practical. A careful medical history and physical examination are essential. Validated symptom scores, urine test, uroflowmetry, and postvoid urine residual, as well as frequency-volume charts for patients with nocturia or predominately storage symptoms should be used. Prostate-specific antigen should be ordered if a diagnosis of prostate cancer changes the treatment plan. Urodynamics should be performed for selected patients. Men with mild symptoms are candidates for watchful waiting. Behavioural modification should be offered to men with LUTS prior to, or concurrent with, treatment. The choice of medical treatment depends on the assessment findings, predominant type of symptoms, ability of the treatment to change the findings, and the expectations to be met in terms of the speed of onset, efficacy, side effects, and disease progression. Surgery is reserved for men with absolute indications, and for patients who fail or prefer not to receive medical therapy. Surgical management has been divided into five sections: resection, enucleation, vaporisation, and alternative ablative and nonablative techniques. The choice of surgical technique depends on patient’s characteristics, expectations, and preferences; surgeon’s expertise; and availability of modalities. The guidelines provide an evidence-based approach for the management of male LUTS. A clinical assessment should identify the cause(s) of symptoms and define the clinical profile and patient’s expectations. The treatment should aim to ameliorate symptoms and reduce the risk of complications.